Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several key content areas (cardiovascular prevention, mechanism/LDL lowering, and common adverse reactions) are broadly supported by the provided label excerpts, but multiple time-course and incidence-specific safety claims are not supported by the provided label text, and some adverse-effect lists include items not shown as common in the provided excerpts. Overall alignment is partial.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to prevent cardiovascular disease.
Section 1.1 (Prevention of Cardiovascular Disease) includes indications to reduce risk of myocardial infarction, stroke, revascularization/angina, etc.
Lipitor (atorvastatin) is used to lower cholesterol levels.
Section 14.2 (Hyperlipidemia) states LIPITOR reduces total-C, LDL-C, VLDL-C, apo B, and TG (and increases HDL-C).
Muscle side effects from Lipitor (muscle pain or weakness) can occur at any time during treatment.
Not explicitly supported by the provided excerpts (no timing statement in Section 5.1/6 excerpts). Marked as unsupported in this audit.
Unsupported Statements
The most common side effects of Lipitor include muscle pain or weakness, diarrhea, abdominal pain, nausea, vomiting, headache, fatigue, sleep disturbances, dizziness, and rash.
Provided label excerpts list specific common adverse reactions leading to discontinuation (e.g., myalgia, diarrhea, nausea, alanine aminotransferase increase, hepatic enzyme increase) and commonly reported adverse reactions (nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection). The remainder of the listed items (abdominal pain, vomiting, headache, fatigue, sleep disturbances, dizziness, rash) are not shown in the provided common/adverse-reaction excerpts.
Most adverse events of Lipitor occur within the first 30 days of treatment.
No time-to-onset/adverse-event distribution by 30 days is provided in the included label excerpts.
71% of adverse events were reported during the first 30 days of Lipitor treatment.
No numeric evidence for this percentage or time window is provided in the included label excerpts.
The incidence of adverse events is highest during the first 2 months of Lipitor treatment.
No label excerpt provided gives incidence by time window (e.g., first 2 months).
55% of patients experienced at least one adverse event during the first 2 months of Lipitor treatment.
No numeric evidence for this percentage is provided in the included label excerpts.
Muscle side effects from Lipitor (muscle pain or weakness) can occur at any time during treatment.
The provided label excerpt on skeletal muscle (Section 5.1) does not state that muscle side effects can occur at any time during treatment.
Muscle pain or weakness was reported by 12.8% of patients within the first 30 days of Lipitor treatment.
No provided label excerpt includes this time-window incidence for muscle-related symptoms.
Muscle pain or weakness was reported by 21.1% of patients within the first 60 days of Lipitor treatment.
No provided label excerpt includes this time-window incidence for muscle-related symptoms.
Liver enzyme elevation can occur at any time during Lipitor treatment.
The provided label excerpt on liver dysfunction (Section 5.2) provides incidence of persistent transaminase elevations and monitoring timing, but does not state that liver enzyme elevations can occur at any time during treatment.
Liver enzyme elevation was reported by 4.5% of patients within the first 30 days of Lipitor treatment.
No provided label excerpt includes this time-window incidence for liver enzyme elevations.
Liver enzyme elevation was reported by 8.1% of patients within the first 60 days of Lipitor treatment.
No provided label excerpt includes this time-window incidence for liver enzyme elevations.
Most side effects of Lipitor occur within the first few weeks to months of starting treatment.
No provided label excerpt includes a general time-course distribution for side effects.
Contradictions
Important Omissions
No explicit label-supported monitoring or safety management instructions were provided in the AI claims beyond 'contact a doctor immediately' (e.g., label describes liver function tests prior to and at 12 weeks after initiation and after dose increases; skeletal muscle risk/withholding/discontinuation for serious myopathy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported time-window incidence claims and an expanded 'most common side effects' list that is not fully shown in the provided label excerpts could mislead expectations about when and which adverse effects are most likely, though there are no direct contradictions with the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Numerous incidence/time-course and extended adverse-effect list items are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or revise time-window percentage claims (e.g., 30-day/60-day/2-month percentages) and limit 'most common side effects' to the specific adverse reactions enumerated in the provided label excerpts (Sections 6.1/6.2), or include only those directly supported by the label text provided.